LILLE, France & PARIS--(BUSINESS WIRE)--4P-Pharma, a clinical-stage startup based in Lille that develops disease-modifying therapies for untreated serious diseases, is delighted to welcome Marina Vasiliou, Christian Bechon, and Alain Sainsot as independent and non-executive members to its Board of Directors..

法国里尔和巴黎--（商业新闻短讯）--4P Pharma是一家总部位于里尔的临床阶段初创公司，为未经治疗的严重疾病开发疾病缓解疗法，很高兴欢迎Marina Vasiliou，Christian Bechon和Alain Sainsot成为其董事会的独立非执行成员。。

These novel additions will strengthen 4P-Pharma's goal to become a commercial-stage, fully integrated biopharma company covering the whole value chain from discovery to commercialization.

这些新的增加将加强4P Pharma成为商业阶段的目标，全面整合生物制药公司，涵盖从发现到商业化的整个价值链。

Revital Rattenbach, CEO of 4P-Pharma, says: 'We proudly welcome three exceptional leaders to our Board of Directors. Each new member brings substantial expertise and proven leadership abilities, which are crucial to 4P-Pharma during this period of significant company growth.'

4P Pharma首席执行官RevitalRattenbach表示：“我们骄傲地欢迎三位杰出的领导者加入我们的董事会。每个新成员都带来了丰富的专业知识和经验证的领导能力，这在4P制药公司这一重要的公司增长时期至关重要。”

Concerning the new members:

关于新成员：

Marina Vasiliou, Biogen France President and Managing Director

Biogen法国总裁兼总经理Marina Vasiliou

Marina Vasiliou has been serving as the President and Managing Director of Biogen France since 2021. Biogen is a pioneering international biotechnology company at the forefront of science and innovation, developing tomorrow's medicines in neurology, neuropsychiatry, immunology, and rare diseases. Marina Vasiliou's insights are essential in navigating regulatory requirements and market access strategies.

自2021年以来，Marina Vasiliou一直担任Biogen France的总裁兼董事总经理。Biogen是一家领先的国际生物技术公司，位于科学和创新的前沿，开发神经病学，神经精神病学，免疫学和罕见疾病的未来药物。Marina Vasiliou的见解对于引导监管要求和市场准入策略至关重要。

She has experience managing commercial launches and reimbursement in different international settings, including the US, mainly in chronic and rare disease therapies..

她拥有在包括美国在内的不同国际环境中管理商业启动和报销的经验，主要是在慢性病和罕见病治疗方面。。

'Contributing with my global commercial leadership expertise to supporting 4P-Pharma ambition fills me with great satisfaction. I fully believe in the company's mission to enhance patients' access to first-in-class therapies for untreated serious diseases. I trust the commitment and innovation of 4P-Pharma's CEO and executive team, and I am thrilled to work with them on a diverse Board of Directors,' declared Marina Vasiliou..

“用我的全球商业领导力专业知识来支持4P制药的雄心壮志，我感到非常满意。我完全相信该公司的使命，即为未经治疗的严重疾病增加患者获得一流治疗的机会。玛丽娜·瓦西里奥（MarinaVasiliou）表示：“我相信4P Pharma首席执行官和执行团队的承诺和创新，我很高兴能与他们在多元化的董事会中合作。”。。

Christian Bechon, Senior Partner chez Isalys Augmented Management

Christian Bechon，高级合伙人chez Isalys Augmented Management

Christian Bechon is the former Chairman and CEO of LFB Group. Under his leadership, LFB Group has transformed from a French leader in plasma cell fractionation to an internationally recognized player with a global footprint.

Christian Bechon是LFB Group的前董事长兼首席执行官。在他的领导下，LFB集团已从法国浆细胞分离领域的领导者转变为全球知名的球员。

'4P-Pharma is a promising French biotech company that prioritizes patients' needs. The company's main objective is to contribute to healthcare innovation in France and Europe while maintaining its independence. I am privileged to be a part of this entrepreneurial journey and provide valuable guidance to the leadership team to catalyze 4P-Pharma’s next wave of growth,' said Christian Bechon..

“4P Pharma是一家有前途的法国生物技术公司，优先考虑患者的需求。该公司的主要目标是为法国和欧洲的医疗创新做出贡献，同时保持其独立性。克里斯蒂安·贝孔（ChristianBechon）说：“我很荣幸能成为这段创业之旅的一部分，并为领导团队提供宝贵的指导，以推动4P制药的下一波增长。”。。

Alain Sainsot, GTP Bioways founder and President

GTP Bioways创始人兼总裁Alain Sainsot

Alain Sainsot, Founder and President of GTP Bioways, has served as Senior Director of Group Operations and Logistics for leading pharmaceutical companies like Pierre Fabre. He is a serial industrial entrepreneur who created two fast-growing CDMOs, Amatsi-group (acquired) and GTP-Bioways. He brings extensive experience in the industrial anchor of drug development to 4P-Pharma..

GTP Bioways创始人兼总裁阿兰·塞恩索特（AlainSainsot）曾担任皮埃尔·法布尔（PierreFabre）等领先制药公司的集团运营和物流高级总监。他是一位连续的工业企业家，创建了两个快速增长的CDMO，Amatsi group（被收购）和GTP Bioways。他为4P制药公司带来了丰富的药物开发行业经验。。

'It is an honor for me to join 4P-Pharma in their mission to develop innovative drugs for patients. I am confident in Revital Rattenbach's dedication and her leadership team's commitment to providing first-in-class treatments to patients. I look forward to joining forces and implementing the highest quality standards to industrialize 4P-Pharma's promising therapeutic pipeline further,' stated Alain Sainsot..

“我很荣幸加入4P制药公司，为患者开发创新药物。我对RevitalRattenbach的奉献精神和她的领导团队为患者提供一流治疗的承诺充满信心。阿兰·塞恩索特（AlainSainsot）表示：“我期待着联合起来，实施最高质量标准，使4P制药公司有前途的治疗管道进一步工业化。”。。

Concerning the Board of Directors of 4P-Pharma

关于4P Pharma董事会

These new members reinforce the existing 4P-Pharma Board of Directors, which is composed of robust and well-known life science experts.

这些新成员加强了现有的4P制药董事会，该董事会由强大而知名的生命科学专家组成。

Their comprehensive industry knowledge and extensive network strengthen the company's credibility and strategic vision in the biotech and pharma sectors.

他们全面的行业知识和广泛的网络增强了公司在生物技术和制药领域的信誉和战略愿景。

Jean Pierre Lehner, Chairman of the 4P-Pharma Board of Directors, concluded: 'I am thrilled by Marina Vasiliou, Christian Bechon, and Alain Sainsot's enthusiasm for joining our Board. Their combined expertise will accelerate our mission and strengthen our ability to bring innovative therapies to those in need.'.

4P制药公司董事会主席让·皮埃尔·莱纳（Jean-PierreLehner）总结道：“我对玛丽娜·瓦西里奥（MarinaVasiliou）、克里斯蒂安·贝孔（ChristianBechon）和阿兰·塞恩索特（AlainSainsot）加入我们董事会的热情感到兴奋。他们的综合专业知识将加速我们的使命，增强我们为有需要的人带来创新疗法的能力。”。

About 4P-Pharma

关于4P Pharma

Founded in 2014, 4P-Pharma is a clinical-stage biotechnology company based in Lille dedicated to developing innovative curative therapies for severe diseases with unmet medical needs. Our goal is to bring first-class medicines to patients rapidly. 4P-Pharma leverages drug candidates with reduced development times, partly thanks to regulatory opportunities (emergency use or conditional market authorization) with strong intellectual property.

4P Pharma成立于2014年，是一家总部位于里尔的临床阶段生物技术公司，致力于为未满足医疗需求的严重疾病开发创新的治疗方法。我们的目标是迅速为患者提供一流的药物。4P Pharma利用开发时间缩短的候选药物，部分原因是具有强大知识产权的监管机会（紧急使用或有条件的市场授权）。

The company is headquartered in Lille and Paris and has over 20 employees..

该公司总部位于里尔和巴黎，拥有20多名员工。。

Website: https://www.4movingbiotech.com/

网站：https://www.4movingbiotech.com/

LinkedIn: https://fr.linkedin.com/company/4moving-biotech

LinkedIn：https://fr.linkedin.com/company/4moving-biotech

X: https://twitter.com/4Moving_Biotech

X: https://twitter.com/4Moving_Biotech

The only version of the 4P-Pharma press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.

4P Pharma新闻稿唯一具有法律约束力的版本是其原始语言版本。。翻译后的新闻稿文本不应被视为官方文本。